or Try an Advanced Search...

    Treatment Of Chronic Obstructive Pulmonary Disease Stocks List

    Symbol Grade Name % Change
    APLS F Apellis Pharmaceuticals, Inc. 0.52
    INVA B Innoviva, Inc. -1.74
    LUNG D Pulmonx Corporation -0.68
    VRNA F Verona Pharma plc -0.87
    VTVT C vTv Therapeutics Inc. 5.22
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Chronic Obstructive Pulmonary Disease Medicine Pulmonary Disease Asthma Biopharmaceutical Clinical Medicine Inflammatory Diseases Phosphodiesterase Acquired Hemolytic Anemia Alzheimer's Disease Antero Autoimmune And Inflammatory Disease Autoimmune Disease Balloon Catheter Biotie Therapies Buparlisib Catheter Combination Drugs Complement System Copd

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Chronic Obstructive Pulmonary Disease stocks.

    Symbol Grade Name Weight
    ACTV C LeaderShares Activist Leaders ETF 3.62
    PJP A PowerShares Dynamic Pharmaceuticals 3.53
    SIXS A 6 Meridian Small Cap Equity ETF 2.31
    BBP D BioShares Biotechnology Products Fund 1.8
    BTEC D Principal Healthcare Innovators Index ETF 1.32
    View all Treatment Of Chronic Obstructive Pulmonary Disease ETFs...
    Compare ETFs
    Compare ACTV to BBP Compare ACTV to PJP Compare SIXS to BTEC

        Treatment Of Chronic Obstructive Pulmonary Disease Stocks Recent News

        Date Stock Title
        May 9 VTVT vTv Therapeutics GAAP EPS of -$1.17, revenue of $1M
        May 9 VTVT vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
        May 9 VRNA Verona Pharma gets $650M in financing ahead of June FDA decision on COPD asset
        May 9 VRNA Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript
        May 9 VRNA Verona Pharma GAAP EPS of -$0.04 beats by $0.09
        May 9 VRNA Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
        May 9 VRNA Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
        May 9 APLS Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
        May 8 INVA Innoviva GAAP EPS of $0.46, revenue of $77.5M
        May 8 INVA Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
        May 8 APLS Apellis stock sell-off over Syfovre sales "overdone," says Citi
        May 8 APLS Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
        May 8 VRNA Verona Pharma Q1 2024 Earnings Preview
        May 8 INVA Innoviva to Participate in the BofA Securities Health Care Conference
        May 8 APLS Apellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
        May 8 APLS Apellis Pharmaceuticals Inc (APLS) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
        May 7 APLS Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 7 APLS Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transcript
        May 7 APLS Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
        May 7 APLS Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Chronic Obstructive Pulmonary Disease Medicine Pulmonary Disease Asthma Biopharmaceutical Clinical Medicine Inflammatory Diseases Phosphodiesterase Acquired Hemolytic Anemia Alzheimer's Disease Antero Autoimmune And Inflammatory Disease Autoimmune Disease Balloon Catheter Biotie Therapies Buparlisib Catheter Combination Drugs Complement System Copd
        Treatment Of Chronic Obstructive Pulmonary Disease

        Browse All Tags